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Abstract
Background: Inadequate illness recognition and access to antibiotics contribute to high case fatality from infections in
young infants (,2 months) in low- and middle-income countries (LMICs). We aimed to address three questions regarding
access to treatment for young infant infections in LMICs: (1) Can frontline health workers accurately diagnose possible
bacterial infection (pBI)?; (2) How available and affordable are antibiotics?; (3) How often are antibiotics procured without a
prescription?
Methods and Findings: We searched PubMed, Embase, WHO/Health Action International (HAI), databases, service provision
assessments (SPAs), Demographic and Health Surveys, Multiple Indicator Cluster Surveys, and grey literature with no date
restriction until May 2014. Data were identified from 37 published studies, 46 HAI national surveys, and eight SPAs. For
study question 1, meta-analysis showed that clinical sign-based algorithms predicted bacterial infection in young infants
with high sensitivity (87%, 95% CI 82%–91%) and lower specificity (62%, 95% CI 48%–75%) (six studies, n= 14,254). Frontline
health workers diagnosed pBI in young infants with an average sensitivity of 82% (95% CI 76%–88%) and specificity of 69%
(95% CI 54%–83%) (eight studies, n= 11,857) compared to physicians. For question 2, first-line injectable agents (ampicillin,
gentamicin, and penicillin) had low variable availability in first-level health facilities in Africa and South Asia. Oral amoxicillin
and cotrimoxazole were widely available at low cost in most regions. For question 3, no studies on young infants were
identified, however 25% of pediatric antibiotic purchases in LMICs were obtained without a prescription (11 studies, 95% CI
18%–34%), with lower rates among infants,1 year. Study limitations included potential selection bias and lack of neonatal-
specific data.
Conclusions: Trained frontline health workers may screen for pBI in young infants with relatively high sensitivity and lower
specificity. Availability of first-line injectable antibiotics appears low in many health facilities in Africa and Asia. Improved
data and advocacy are needed to increase the availability and appropriate utilization of antibiotics for young infant
infections in LMICs.
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Introduction
In 2010, there were an estimated 6.8 million cases of possible
severe bacterial infection (pSBI), including 2.5 million cases of
meningitis, pneumonia, sepsis or tetanus, diagnosed in neonates in
South Asia, sub-Saharan Africa, and Latin America [1]. The
incidence of neonatal infection ranges from 5.5 cases/1,000 live
births for blood culture-confirmed infections in first-level facilities,
to as high as 170 cases/1,000 births for clinically diagnosed pSBI
in community-based settings [2]. Neonatal sepsis, pneumonia, and
meningitis are the most common severe infections in the first
month of life, and resulted in ,718,000 neonatal deaths globally
in 2010 [3]. Infections account for approximately 23% of neonatal
deaths, yet as high as 50% in low-income settings [3,4]. Numerous
factors place newborns in low- and middle-income countries
(LMICs) at higher risk for developing and dying from infections.
Risk factors for neonatal infections, such as maternal infections,
unhygienic delivery care, preterm birth, and intrauterine growth
restriction are more prevalent in LMICs [5]. Furthermore, case
fatality from neonatal infections is as high as 40% in LMICs, in
large part due to poor access to appropriate medical care and
antibiotics [5–8].
Timely and adequate diagnosis and treatment of bacterial
infections with antibiotics are critical to reduce global neonatal
and child mortality [9,10]. Neonatal infections are difficult to
recognize, even in high-resource settings, because their symptoms
are non-specific and clinical infection is corroborated by positive
cultures in only 3%–10% of suspected cases [2,11,12]. Diagnosis is
challenging in low-resource settings where little or no capacity for
etiological diagnosis or laboratory testing exists, and providers
must often rely on clinical symptoms and algorithms alone. The
extension of the WHO Integrated Management of Childhood
Illness (IMCI) strategy to include newborns, coupled with the
development and validation of clinical algorithms for young
infants (,2 months) [13,14], have been critical steps to improving
the detection of very severe disease (VSD), including pSBI, in these
settings. Case management of pSBI in first-level facilities and
communities is feasible and may reduce neonatal mortality by
34%–62% [15–17]. In a systematic review of studies reporting the
etiology of community acquired neonatal sepsis from LMICs, the
common major pathogens were Staphylococcus aureus (26% of
blood culture isolates), Klebsiella (21%), and Escherichia coli (8%),
while Group B strep was uncommon (2%) [18], although regional
differences have been noted [19]. Currently, WHO recommends
as first-line treatment for neonatal sepsis injectable gentamicin and
procaine benzylpenicillin for ten days, and as second line,
ceftriaxone treatment for ten days [20]. These antibiotics are
now on the WHO Model List of Essential Medicines for Children
and have been targeted by the United Nations Commission for
Life-Saving Commodities for Women and Children as key
commodities to reduce neonatal mortality [21].
In order for governments and health systems to prioritize this
high-impact, evidence-based intervention, it is imperative to
understand the current landscape of access to antibiotics for
treating neonatal infections in developing countries. Antibiotic
access deserves special consideration in neonates, infants, and
children, given their specialized dosing, drug formulations,
delivery routes, risk profile, physiology, and monitoring needs
[21,22]. Furthermore, optimal antibiotic choice may vary region-
ally, depending on local pathogens, resistance patterns, drug
availability, and cost [23].
The objective of this study was to review the broad landscape of
factors affecting access to treatment for neonatal infections in
LMICs, in order to identify key barriers and bottlenecks. We
developed a conceptual framework to describe the potential
pathways that may be taken from the point of illness recognition to
the receipt and use of an antibiotic in a newborn (Figure 1). We
have recently reviewed the literature on care-seeking patterns by
caregivers for newborn illness [24], which is the first critical step
required to access treatment for neonatal infections, as well as
access to health facilities [25]. Once a caregiver suspects illness in a
newborn and decides to bring the infant to a health provider, the
provider must recognize whether an illness is a possible bacterial
infection (pBI) requiring an antibiotic and subsequently prescribe the
antibiotic. The prescriber may be a trained medical provider (e.g., a
doctor, a nurse, or a midwife), a pharmacist, or a health worker who
may or may not have been trained through the formal medical system
(e.g., community health worker [CHW], traditional birth attendant,
or traditional healer). Alternatively, parents may self-prescribe
antibiotics where antibiotics are openly available over the counter.
After being prescribed the antibiotic, factors influencing acquisition
include antibiotic availability and affordability. Antibiotics may be
obtained from pharmacies or within health facilities, either from the
public or private sector, and informally from drug stores, street
vendors, markets, or traditional healers. Government subsidies or
health insurance may cover a substantial fraction or the entire cost of
some medications in the public sector and help increase affordability
particularly for the poor, while cost markup in the private sector may
inflate prices and reduce affordability. After purchase, the parent
must decide to give the antibiotic to the newborn. Finally, many
factors may affect antibiotic utilization, such as antibiotic formulation,
concentration, taste, and toxicities.
For this analysis, we systematically reviewed the literature to
answer the following specific study questions within the above
described framework: (1) Can frontline health workers use clinical
sign algorithms to accurately diagnose possible bacterial infection
in young infants, as compared to physicians? (2) How available
and affordable are antibiotics for treating neonatal infections in
health facilities/pharmacies in LMICs? (3) What fraction of
antibiotic purchases for treating neonatal/pediatric infections is
accessed without prescription by a health provider (i.e., over-the-
counter) in LMICs?
Methods
Literature Review and Data Sources
We conducted a systematic review of the published and grey
literature, which was originally done between February and
September 2010, updated in June 2013 and May 2014, with no
date restrictions (Figure 2). The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement for
the systematic review is available in Text S1. The searches
occurred in phases to address each of the study questions, and the
detailed search strategy and terms are shown in Text S2.
Databases searched included PubMed, Embase, WHO regional
databases (LILACS, IMEMRO, AIM), POPLINE, and Cochrane
(review protocol available in Text S3). We also reviewed
bibliographies of sentinel articles. Grey literature sources included
Eldis, UN, UNICEF, and donor websites (USAID, Saving Newborn
Lives, Healthy Newborn Network). Demographic and Health
Surveys (DHS), Multiple Indicator Cluster Surveys (MICS), service
provision assessments (SPAs), and WHO Health Action Interna-
tional (HAI) global databases were searched. SPAs are conducted in
a nationally representative sample of .400 health facilities,
including government, general, and specialized facilities as well as
facilities in the non-governmental, private-for-profit, and non-profit
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sectors. Each SPA conducted includes a facility audit to assess
infrastructure, equipment, and pharmacy. WHO HAI developed a
standardized methodology for assessing drug availability and
affordability in LMICs in 2003 [26]. In brief, data are collected
from at least four different geographic areas in a nation, using a
random cluster sample of public facilities and private retail
pharmacies. In large countries, sub-national surveys are also
conducted. Data collectors visit selected medicine outlets and
obtained data on availability and pricing on a list of 30 WHO
essential drugs on a particular day.
Inclusion Criteria
There were no language restrictions. If potential articles of
interest were identified in non-English languages, the abstract was
translated to English via Google Translate to determine whether
the article met inclusion criteria. Articles were considered for
inclusion if they were from LMICs, as defined by the World Bank,
and reported data to inform one of the research questions. We
included searches for specific infections (sepsis, meningitis,
pneumonia, urinary tract infection, omphalitis) as well as broader
terms for the clinical diagnosis of infection (IMCI, algorithms,
possible serious bacterial infection). We included articles that
reported on pBI of any severity, including pSBI (sepsis, meningitis,
pneumonia) as well as local bacterial infection (omphalitis or skin
infections). A neonate was defined as ,28 days of age and a young
infant ,2 months of age. For study question 1, the study
population included newborns and young infants. For study
question 2, we included availability and affordability data on
common first- and second-line injectable antibiotics and formu-
lations for treating neonatal infections including ampicillin,
penicillin or procaine benzylpenicillin, gentamicin, and ceftria-
xone, and also extracted data on oral amoxicillin and cotrimox-
azole [22,27]. For oral agents, we extracted data on suspension
formulation when available, or capsular formulation given the
potential to re-suspend in fluid for neonates. For study question 3,
we determined a priori to include data on the pediatric population
less than five years of age, given the likely paucity of neonatal
specific data.
Exclusion Criteria
We excluded studies that reported on adult populations and
those solely focusing on the inappropriate use of antibiotics. The
goal of this review was to populate a model parameter for ‘‘the
proportion of neonates with possible bacterial infection accessing
antibiotics’’ for a modeling exercise that is described elsewhere
(Rudan I, personal communication). Thus, studies that reported
on antibiotic prescription patterns or utilization without a
denominator to inform this parameter were excluded (i.e., studies
reporting numbers of antibiotic prescriptions with no denomina-
tor, or per WHO/INRUD methodology [antibiotic prescriptions
per patient encounter, population, or total prescriptions]) [28]. We
excluded studies from specialized sub-populations or high-income
countries, individual case reports, duplicate studies, and studies
reporting on outbreaks or susceptibility patterns alone.
Data Abstraction
Data were abstracted into a standard excel file developed for
Child Health Epidemiology Reference Group (CHERG) reviews
[29] by two independent reviewers. Data regarding population
characteristics, population selection, study design, setting, age
range, case definitions of possible infection, gold/reference
standard diagnosis, antibiotic prescription, availability, or cost
were recorded. For study question 1 (the accuracy of pBI
diagnosis), a two-by-two table was constructed for each study to
determine the true positives, false positives, true negatives, and false
negatives, comparing clinical algorithm to the gold standard reference
definition. In validation studies, if the performance of more than one
algorithm was presented, the ‘‘best’’ algorithm chosen by the authors
(typically the one with the highest sensitivity) was used in the analysis.
For study question 2, the proportion of medicine outlets with specified
antibiotics for treating neonatal infection were recorded, and the
number of outlets (pharmacies or facilities surveyed if available).
From the WHO HAI database, the following data were abstracted
regarding neonatal antibiotic formulations: availability (percent of
venues that carry a medication on the day of data collection), pricing
(unit price in US dollars), and affordability (number of days of work
required by the lowest paid unskilled government worker to purchase
a course of antibiotic treatment). For study question 3, data were
abstracted on the overall number of pediatric antibiotic purchases or
courses over a specified time period, and the number (or proportion)
of those that were obtained by self-medication, or without a health
provider prescription.
Study Quality Assessment
For study question 1 (accuracy of pBI diagnosis), methodolog-
ical quality was assessed per the Cochrane Diagnostic Test
Accuracy Working group recommendations [30] using the
QUADAS-2 (Quality Assessment of Diagnostic-Accuracy Stud-
ies-2) [31]. For study questions 2 and 3, the individual and overall
study quality was assessed based on a modification of GRADE
[32] methods for systematic reviews described by CHERG, using
principles relevant for the aims of this particular review [29].
Individual studies were evaluated for limitations and biases in
the following domains: study design, population selection and
representativeness, definitions, precision, and generalizability to
the population of interest [24]. For each of these domains, a score
was assigned (0, no limitations; 1, some limitations; and 2, serious
limitations). A total quality assessment score was given to each
study. Study design was scored according to whether data were (a)
prospectively or retrospectively collected, and potentially influ-
enced by recall bias, (b) directly observed versus self-reported
(reporting bias), and by (c) potentially biased by high rates of losses
to follow-up. Population representativeness described the extent to
which the study sample was representative of the general
population as being either population or health facility-based with
minimal or moderate bias. Quality of definitions described the
extent to which study defined and characterized the parameter of
interest. Consistency was assessed across all studies to ascertain the
extent to which these definitions were similar. Generalizability was
defined according to the degree to which results could be applied
to our target population of interest (newborns in LMICs). Precision
was defined as the extent to which the study populations included
a sufficient sample size. If a study’s total study population was less
than 50, the quality of the evidence was considered insufficient to
generalize the effect of the outcome to the target population [33].
All studies were graded independently by two reviewers, and
discrepancies in scoring were discussed and resolved. The study
database and quality assessment are in Table S1.
Data Analysis
Study question 1: diagnosis of pBI in young
infants. Coupled forest plots were generated with Review
Manager 5.1. Pooling of sensitivity and specificity separately fails
to account for the inter-relatedness of the measures. Hierarchal
bivariate models are recommended for meta-analysis [30] and
were analyzed using the Stata 12.0 ‘‘metandi’’ command, and
hierarchal summary receiver operating characteristic curves were
generated with the ‘‘metanplot’’ command. Sub-group analysis
Access to Treatment for Young Infant Infections in LMICs
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was conducted by health worker type and gold standard reference
diagnosis type (clinical versus laboratory/radiologic evidence).
Subgroups with fewer than four studies were pooled by univariate
random effects (‘‘metan’’ command) given the failure of the
metandi command to converge with less than four studies. Meta-
regression was conducted using the Stata ‘‘metareg’’ command,
and logit transformed proportions and standard errors were
calculated to explore the significance of sources of heterogeneity
(type of health worker, reference standard diagnosis, location
[community versus facility]).
Study question 2: antibiotic availability, pricing, and
affordability. Given the differing methodology and sampling
frame from the studies identified in the literature, WHO HAI
Project, and SPAs, the survey data from different sources were not
combined and are reported separately. From the HAI database,
national survey data on availability, pricing, and affordability were
grouped and analyzed by WHO major world regions. If a
particular country had data from more than one year, we used the
most recent survey data; if multiple sub-national surveys were
conducted, we calculated a national mean for the country. For
availability, we used data from the brand (originator, most sold
generic or lowest price generic) of highest availability for the
survey. Antibiotic pricing was calculated for treating a 3 kg
newborn for a ten-day treatment course based on recommended
neonatal dosing and duration from several recent reviews
[22,27,34]. Affordability data were available from the WHO
HAI database for cotrimoxazole and amoxicillin suspensions. For
injectable antibiotics, affordability was calculated by dividing the
price of the full course of antibiotic by the daily wage of the lowest
paid government worker. For each WHO region sub-group, the
median data point and range were calculated for each indicator
(availability, price, and affordability).
Study question 3: non-prescription antibiotic
use. Proportions and standard errors were logit transformed,
and meta-analysis was conducted with random effects, assuming
that the true prevalence of non-prescription antibiotic use may
vary between studies. The Higgins I2 statistic and 95% confidence
intervals were calculated. Meta-regression was conducted to
explore sources of heterogeneity (age group, region). Stata 12.0
was used for these analyses.
Registration
The review was registered in the PROSPERO International
prospective register of systematic reviews (CRD42013004586).
Results
In the literature review, a total of 2,554 titles were identified,
and after reviewing titles and/or abstracts, we retrieved 261 full
articles (Figure 2), of which 37 met study criteria. These results
and findings from SPAs and HAI databases are reported within
each study question.
Study Question 1. Diagnosis of pBI in Young Infants
We identified a total of 14 studies in the literature that reported
on health worker diagnosis of pBI (Table 1). Eleven studies
reported on a population of young infants (,2 months) with four
of those studies excluding ,7 day old infants, and three which
reported on neonates (,1 month). In SPA and DHS surveys, there
were no data identified on pBI diagnosis in young infants. None of
Figure 1. Conceptual model of access to antibiotics for newborns with infection.
doi:10.1371/journal.pmed.1001741.g001
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the studies indicated the proportion of preterm or low birth weight
babies in the validation sample. Nine assessments were conducted
in facilities (outpatient clinics, primary care clinics, or emergency
department assessments), and five were conducted within the
community. Six studies reported on the accuracy of clinical-sign-
based diagnosis of pBI by varying IMCI algorithms compared to a
gold standard diagnosis by an expert physician, which included
laboratory and radiologic testing. The remaining compared IMCI
classification between first-level, frontline health workers and
physicians. Health workers ranged from CHWs (n=4), first-level
facility-based health workers (n=6), to pediatricians (n=3). Five
studies reported on the diagnosis of severe illness (pSBI or VSD)
and the remaining reported on any pBI (‘‘need for referral,’’
‘‘yellow OR red zone’’ on IMCI).
The individual study quality assessment is in Table S1, and the
overall QUADAS-2 summary assessment is shown in Figure S1.
There was high risk of bias in patient selection in eight studies, and
unclear risk in three out of 14 studies. The blinding of the
reference classification to the index assessment for pBI was unclear
in nine studies; however, in all studies the index assessment was
blinded to the gold standard. Eleven studies were included in the
meta-analyses (including 15,499 neonates, 3,016 possible infection
cases) (Table 2). Three studies were excluded from meta-analyses
because they did not have sufficient data from which to calculate
sensitivity/specificity [35,36] or the gold standard was a computer
algorithm and not physician diagnosis [37].
Can clinical sign algorithms accurately predict severe
disease in young infants? The WHO Young Infants Study
(YIS) was the sentinel multi-country study (1990–1993) from four
countries (Ethiopia, Gambia, Papua New Guinea, Philippines) that
informed the development of IMCI guidelines for the manage-
ment of sick young infants in first-level facilities [38]. In the
analysis of young infants ,60 days (n=3,303), the presence of one
of 14 clinical signs assessed by a pediatrician or a study nurse
predicted severe bacterial infection (sepsis, meningitis, hypoxemia,
or radiologic proven pneumonia) in infants ,2 months with a
sensitivity of 87% and specificity of 54% [38]. While some clinical
signs were more predictive of specific types of infections (i.e.,
bulging fontanelle or convulsions for meningitis, or chest
indrawing for pneumonia), a single algorithm was chosen to
indicate any pSBI given the overlapping non-specific signs in
young infants and low prevalence of individual conditions. Serious
bacterial infections were detected in 11% of these infants
(meningitis [n=35], sepsis [n=120], and pneumonia [n=259])
Figure 2. Search strategy and results for literature review of published and grey literature.
doi:10.1371/journal.pmed.1001741.g002
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and the common isolated pathogens were S. aureus, Streptococcus
pneumonia, and E. coli, with E. coli gram negatives more
important in the first week of life. In Kilifi District Hospital,
Kenya, English and colleagues reported that the 16-sign IMCI
guidelines for infants 7–59 days predicted very severe illness with a
sensitivity of 97% and specificity of 44%, and for infants ,7 days
with sensitivity 94% and specificity 25%. The Young Infant
Clinical Signs Study enrolled 8,889 children from five countries
(Bangladesh, Bolivia, Ghana, Pakistan, South Africa) [39]. This
study aimed to identify any severe illness in young infants
requiring hospital admission, and was not limited to severe
bacterial infections alone. Among those babies who required
admission among the study infants, the conditions varied between
study sites with rates of severe infection (sepsis, meningitis,
pneumonia) ranging from 23% in Bolivia to 70% in Pakistan
among infants 7–59 days. Prematurity/low birth weight was the
cause of admission for 0% (Bolivia) to 17% (Bangladesh) of infants
in the first week, while birth asphyxia accounted for 0% (Bolivia) to
41% (Bangladesh). After this study, the WHO IMCI guidelines
adopted a simpler algorithm including seven signs. When
performed by primary health workers, the seven-sign algorithm
predicted severe illness requiring hospital-level care with a
sensitivity/specificity of 85%/75% (0–7 days old) and 74%/79%
(7–59 days old) [39]. Of interest, the sensitivity of the algorithms
was lower in the two African countries in this study (Ghana, South
Africa).
In meta-analysis, including six studies that validated diagnosis of
severe disease by IMCI algorithms compared to gold standard
reference of physician diagnosis including corroborating labora-
tory data (blood count, culture, chest X-ray, and/or cerebral
spinal fluid), the average sensitivity was high (86.8%; 95% CI
81.8–90.6) and specificity was lower (62.3%; 95% CI 48.0–74.9)
(Figure 3, forest plot; Figure 4 receiver operating curve; Table 2).
Meta-regression showed significantly lower specificity of IMCI
algorithms, when the gold standard reference definition included
laboratory/radiologic data or was performed in the facility (with
more frequent laboratory/radiologic capacity).
While the diagnostic accuracy of algorithms may vary in
premature babies, who often have similar signs/morbidity as
babies with infection (i.e., jaundice, poor feeding), none of the
studies provided data on the proportion of babies screened who
were either preterm or low birth weight, or stratified the validation
study by these subgroups.
Can frontline health workers use clinical algorithms to
accurately identify severe disease/possible bacterial
infection? The eight studies reporting on the validity of frontline
health workers to diagnose pBI compared to physician diagnosis
(with or without laboratory confirmation) are shown in Table 1.
The six facility-based studies (Table 1) were IMCI evaluations (four
India, one Kenya, one multi-country) with sensitivity/specificity
ranging from 47%/100% for the classification of ‘‘red or yellow’’
zone disease requiring referral in a small evaluation in Raipurani,
India to 96%/40% for a large assessment of the 16-sign IMCI
guideline in Kilifi, Kenya. Among the community-based studies,
two intervention studies from Bangladesh validated CHW
classification of newborns by modified Bangladeshi IMCI
criteria compared to physician classification, reporting that
73%–91% of cases of VSD were recognized by CHWs, with
specificity ranging 95%–98% [40,41].
In the pooled analysis, among all frontline health workers
(facility and community-based), the sensitivity (80.1% [95% CI
70.9–89.2]) and specificity (86.3% [95% CI 72.6–100]) for the
recognition of severe illness (VSD/pSBI) was high (five studies)
(Table 2). For the recognition of all pBI (VSD and PVSD), the
sensitivity was similar, but specificity was lower at 68.5% (eight
studies, 95% CI 54.5–82.5) (Figure 5, forest plot; Figure 6,
receiver operating curve). Meta-regression showed no difference
in sensitivity by health worker type; however, specificity was
significantly modified by the effect of health worker type. For
facility-based health workers, the lower specificity was likely due to
the higher availability of laboratory testing to corroborate the
reference diagnosis. Most studies were graded as having risk for
bias in patient selection given that many studies occurred in health
facilities where parents presented with their sick children. Only
one study was graded as being population-based, with low risk of-
bias in patient selection.
Although three community-based studies provided relevant
data, they were not included in the meta-analysis because they did
not report sensitivity and specificity. In the SEARCH trial in
Gadichiroli, India, village health workers could identify individual
signs of neonatal illness in high agreement with physicians (mean
92.7% agreement on 46 variables) [42], and diagnosed 89% of
cases meeting clinical sepsis criteria compared to a computer
diagnostic algorithm based on neonatal symptoms [37]. In Nepal,
female community health volunteers had high levels of agreement
on the major signs of neonatal sepsis compared to facility-based
CHWs (kappa .0.71 on ten signs) [36]. In Purulia, India, a
program evaluation of government Integrated Management of
Neonatal and Childhood Illnesses (IMNCI) training assessed
frontline health worker performance [35]. Faculty members who
conducted observation of home visits found that while a majority
of infants had individual signs/symptoms assessed, the full IMNCI
assessment was completed in only 32% of cases. Among those
cases, 34.8% had the correct classification in all subgroups and
34.2% in at least one subgroup.
Study Question 2. Antibiotic Availability
We identified data on availability of antibiotics for treating
neonatal infections from three main sources: published literature
(11 studies), WHO/HAI database (46 national surveys), and SPAs
(eight national surveys).
The surveys reported in the published literature were typically
of smaller sample size (,50 outlets), at the regional level
(provincial or district), and of varying sampling methodology.
One study reported on availability of pediatric formulations (i.e.,
suspension/syrup) [43]. Overall the study quality of data reported
in the literature was low and heterogeneous (Table S1), and the
availability of individual antibiotics varied widely between surveys
(Table 3). The data were therefore not pooled and overall ranges
are reported.
From the WHO/HAI database, the regional summary is shown
in Table 4 with country-level data in Table S2. Ampicillin data
were limited, though the drug was highly available in four African
surveys (1 g/vial injection). Procaine benzylpenicillin (4 MIU/vial)
was available in .90% of Ethiopian medicine outlets (2004),
however in Haiti (2010), the 1 MIU preparation had very low
availability at ,10%. Injectable gentamicin had low-moderate
median availability in the public sector in most regions (47%–68%
of outlets, except Western-Pacific), with higher availability in
the private sector (72%–96%). Ceftriaxone was generally less
available, particularly in Africa where a median of 25% of public
facilities had it in stock. Oral amoxicillin (capsules/tablets) and
cotrimoxazole suspension were highly available (.75%) in both
the public and private sector in most regions. The limited data on
amoxicillin suspension (250 mg/5 ml, n=14 surveys) showed high
availability (.90%) in Africa and Eastern Mediterranean regions
(Table S2).
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National SPA surveys provided data on antibiotic availability
based on pharmacy audits conducted in eight countries (Table 5).
Injectable ampicillin, gentamicin, and ceftriaxone had low median
availability in both delivery and primary child care facilities in
Africa and Southeast Asia—available in fewer than half of
facilities. In Africa, injectable penicillin was highly available in
ambulatory pediatric facilities (.80%) although there were no
data on specific formulation of procaine benzyl penicillin. The
availability of oral antibiotics was much higher (.70%), although
the availability of pediatric suspensions was low. Similarly, in
surveys in Bangladesh and Egypt, first-line injectable antibiotic
availability for treating neonatal sepsis was low.
Antibiotic pricing and affordability. Based on pricing data
from the WHO/HAI surveys, the costs and affordability of
treatment for neonatal sepsis (ten-day course for 3 kg baby) were
estimated (Table 6, WHO Regions; Table S2, National Pricing
data; Table S3, Affordability data). The data were from years 2001
to 2013, and were not adjusted for inflation. The estimated costs
for a treatment course of ampicillin in Africa ranged from US$2.34
(public sector) to US$4.02 (private sector), equivalent to 1–1.6 days
of work for the lowest-level government laborer. Injectable
gentamicin pricing was relatively low (,US$1) and affordable
(,0.5 days of work) in most regions. Ceftriaxone was substantially
more expensive across all regions, with private sector pricing
uniformly much higher than public sector costs (reaching as high
as US$40/course in Eastern Mediterranean and Western-Pacific
Regions) and accordingly less affordable. In Africa, a course of
ceftriaxone cost the equivalent of five days of work in the public
sector, and almost 16 days in the private sector. A common finding
was where specific antibiotics were free in the public sector,
availability was low, and private sector availability and cost were
high.
Overall the cost of Amoxicillin capsules was low (,US$1/
treatment course) and affordable (less than one work day) in all
regions, though prices for suspension would be at least 150%
higher. Cotrimoxazole suspension was also low cost and afford-
able, with generally higher markup in the private sector.
Study Question 3. Non-prescription Use of Antibiotics
Table 7 shows the study characteristics of the 12 studies
reporting on non-prescription, over-the-counter use of antibiotics
to treat illness in young children (,7 years of age). Six studies
included infants; however, only one study separately reported use
among the ,1 year old infant age group [44]. One study reported
on use ,3 months of age and none on newborns [45]. Most of the
studies were community-based cross-sectional surveys, while one
study was an observation of pharmacy encounters. The conditions
that were treated varied and included a wide range of illnesses
(tonsillitis, respiratory illness, diarrhea) (Table 7). The overall
quality of evidence on access was generally low (Table S1),
clinically diverse, and statistically heterogeneous (overall I2 96%,
95% CI 95%–97%). Random effects meta-analysis was conducted
(Figure 7), and the global average of proportion of pediatric
antibiotic purchases obtained over-the-counter was 25.1% (95%
CI 18.1%–33.6%). Meta-regression showed no statistically signif-
icant difference based on WHO regional grouping.
While there were few studies that reported specifically on
infants, several studies indicated that non-prescription use may be
lower in the younger ages. In Peru, among infants ,12 months,
self-medication rates were lower at 7.6% compared to 15.9% in
the entire under-five population. Similarly in Brazil, rates of non-
prescription use were 6.5% among children ,2 years old
compared to 28.1% for children 2–7 years of age. In the single
study that reported on self-medication among infants ,3 months
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of age with illness, none of the children in this age group had taken
a non-prescription antibiotic [45].
Discussion
In this landscape review, we found that trained frontline
health workers may use clinical sign algorithms to detect pBI in
young infants with relatively high sensitivity in certain settings,
but lower specificity. Availability of first-line injectable
antibiotics to treat neonatal infections was low in first-level
health facilities in Southeast Asia and Africa, and data on
neonatal-specific formulations were limited. Oral antibiotics
were generally highly available and affordable. The procure-
ment of antibiotics over-the-counter without a prescription was
common in developing countries in children under five,
accounting for one in four antibiotic purchases; while non-
prescription use in young infants may be lower, this needs to be
evaluated with respect to safety and development of antimi-
crobial resistance.
Frontline Health Worker Diagnosis of Severe Disease/pBI
in Young Infants
The development, refinement, and simplification of IMCI
algorithms to identify sick young infants have been a major
advancement to increasing diagnosis of and access to treatment for
neonatal infections in LMICs. These analyses provide evidence
that clinical-sign-based algorithms can detect neonatal infection
with relatively high sensitivity, and that frontline health workers
can use these algorithms to identify pBI with relatively good
sensitivity and lower specificity compared to physician diagnosis.
These data are promising for the 50 million annual home births
and many sick newborns who first present to peripheral facilities.
However, there are also several limitations to these data. Most
of the facility-based validation studies were at risk for selection
bias, given that the assessment was among children for whom
parents sought care for illness. They may have been sicker or
presented at facilities with better trained staff. Given this initial
selection, the sensitivity and specificity of the diagnosis may not
reflect the performance of population-based screening. Studies to
Table 2. Diagnostic accuracy of clinical algorithms and frontline health workers to detect severe disease/possible bacterial
infection in young infants.
Outcome
Number of
Studies
Number of
Screened Infants
Cases of Possible
Infection Detected
by Health Workers
Sensitivity
(95% CI)
Specificity
(95% CI)
Reference Gold Standard
Physician diagnosis
with laboratory or
radiologic testing/results
6 14,254 2,558 86.8% (81.8–90.6) 62.3% (48.0–74.9)
Physician clinical
diagnosis only
5 1,245 458 76.6% (55.6–89.6) 83.5% (56.8–95.2)
Frontline Health Workers
(n=8 studies)
All frontline health
workers (CHW and first
level facility health worker)
(a) VSD 5
(b) PVSD/VSD 8
11,857 (a) VSD 1,272
(b) PVSD/VSD 2,136
(a) VSD: 80.1% (70.9–89.2)
(b) PSVD/VSD 82.0%
(75.7–88.2)
(a) VSD: 86.3% (72.6–100)
(b) PSVD/VSD 68.5%
(54.5–82.5)
First-level
facility-based worker
(a) VSD 3
(b) PVSD/VSD 6
11,174 (a) VSD 1,187
(b) PVSD/VSD 1,965
(a) VSD: 72.5% (55.7–89.3)
(b) PSVD/VSD 85.2%
(78.7–91.7)
(a) VSD: 77.5% (75.8–79.1)
(b) PSVD/VSD 59.2% (39.3–
79.1)
CHW 2 683 (a) VSD 85
(b) PVSD/VSD 171
(a) VSD: 86.8% (71.6–100)
(b) PVSD OR VSD: 66.4%
(25.8–100)
(a) VSD: 97.1% (94.1–100)
(b) PSVD OR VSD: 91.3%
(83.9–98.7)
For VSD (very severe disease), we are including red zone IMCI and pSBI (possible severe bacterial infection).
For PVSD (possible very severe disease), we are including both red AND yellow zone in IMCI, and pSBI as well as possible local bacterial infection.
doi:10.1371/journal.pmed.1001741.t002
Figure 3. Forest plot of studies of diagnostic accuracy of clinical sign (IMCI) algorithms to detect severe disease/pBI in young
infants compared to physician-laboratory diagnosis.
doi:10.1371/journal.pmed.1001741.g003
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determine the sensitivity, specificity, and predictive value of the
algorithms are needed at the population/community level, and
would also be useful to examine by morbidity pattern. Some
studies were from neonatal research studies where quality of
training and care may differ from routine health delivery systems
in LMICs, and the health worker may be aware of their being
assessed. In the larger scale program evaluations of IMNCI in
Purilia, India, only one-third of CHWs actually completed the full
seven-sign assessment and the agreement was much lower than the
data from neonatal research trials. Thus, the performance
reflected in the meta-analysis may reflect an optimal performance
and potentially overrate a programmatic setting. Other limitations
to this analysis included that the clinical sign algorithms varied
between evaluations, and different algorithms may have varying
diagnostic accuracy. The algorithms used were either the IMCI
algorithm at the time of the original study, or the ‘‘best’’
performing algorithm chosen by the authors within the particular
validation studies. Furthermore, preterm infants may share some
clinical signs as newborns with infection, and also carry higher risk
of infection. Thus understanding the validity of these algorithms in
full term versus preterm babies is important; however, none of the
studies provided data to examine this question. Another important
consideration is that the majority of the validation studies included
in the meta-analysis were conducted in South Asia. In the Young
Infant Clinical Signs group study, the algorithm had lower
sensitivity in the two African sites, and the potential influence of
HIV infection was raised by the authors. Thus, these findings may
be more generalizable to similar Asian settings, and further
Figure 4. Receiver operating curve of studies of diagnostic
accuracy of clinical sign algorithms versus physician-laborato-
ry diagnosis of severe disease/pBI in young infants.
doi:10.1371/journal.pmed.1001741.g004
Figure 5. Forest plot of studies of diagnostic accuracy of frontline health worker diagnosis of pBI compared to physician diagnosis.
doi:10.1371/journal.pmed.1001741.g005
Figure 6. Receiver operating curve of studies of diagnostic
accuracy of frontline health worker diagnosis of pBI compared
to physician diagnosis.
doi:10.1371/journal.pmed.1001741.g006
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evaluation is needed in the African setting. Finally, the specificity
of sign-based algorithms was relatively low, particularly when
using a laboratory-based gold standard. The negative impact of
over-referral and overtreatment, including burdening already
strained health systems and enhancement of antibiotic resistance,
remain major challenges. These data emphasize the potential
impact of novel technologies such as biomarkers and low-cost
point of care testing to facilitate the diagnostic process and
improve accuracy of detection of newborn infections.
Antibiotic Availability
The UN Commission for Life-Saving Commodities for Women
and Children has prioritized increasing access to injectable
antibiotics for neonatal sepsis as a key commodity. In our review,
we found that first-line injectable antibiotics to treat neonatal
infections have relatively low and variable availability in Africa
and Southeast Asia, where the majority of global neonatal and
child deaths and infections occur. Injectable first-line agents for
treating neonatal infections (ampicillin and gentamicin) had low-
to-moderate availability in outpatient child health or delivery
facilities in Africa and Southeast Asia, and there were scarce data
on procaine benzylpenicillin (which is low cost and allows once
daily intramuscular dosing). Ceftriaxone, a second-line regimen,
also had low availability particularly in Africa in both SPA and
HAI surveys, with discrepant availability in the public versus
private sector. Overall the evidence on antibiotic availability was
of moderate quality. While the data quality in the literature was
low (primarily sub-national and small sample size), both SPA and
HAI data were nationally representative data, with random
sampling, large samples sizes, and standardized methodology.
However, data on neonatal formulations and concentrations were
generally scarce, particularly when analyzed by region. There
were no data on the lower concentrations of gentamicin (10–
20 mg/ml) or smaller doses for reconstitution of ceftriaxone
(250 mg vials), which are easier to administer in neonates [21].
Future efforts need to routinely collect data in standardized
surveys regarding these essential neonatal medications and
formulations, which are now on the WHOModel List of Essential
Medicines for Children.
Antibiotic Pricing and Affordability
Antibiotic pricing and affordability are critical determinants of
access for the poor. The UN Millennium Development Target 17
specifically aims ‘‘in cooperation with pharmaceutical companies,
to provide access to affordable, essential drugs in developing
countries.’’ Generic brands were typically lower cost than
originator brands, and prices were substantially lower or often
free in the public sector, however availability was often low. An
injectable course of gentamicin for treating neonatal sepsis was
low cost in most regions (,US$1), with slightly higher cost for
ampicillin (US$2–4 in Africa). However, the cost of ceftriaxone
was very high, ranging from ,US$4–US$8 per treatment course
in the public sector in Southeast Asia to over US$30 in the African
public sector. The high cost and low affordability of ceftriaxone
are a major barrier to access for the poor; for example in Africa,
its purchase required a median 16 days of working wages for an
unskilled government employee. A recent report to the UN
Commission on Live-Saving Commodities called for further
investigation into the common supply and manufacturing sources
and national regulatory and financing processes to better
understand the bottlenecks to procurement [21]. Concerted
efforts by pharmaceutical and government agencies need to be
made to increase supply and availability of these essential
antibiotics, particularly neonatal formulations, and reduce costs
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to consumers (by increasing government subsidies or coverage of
these key medications under insurance schemes) and duties and
taxes placed on these medicines, to improve the affordability and
access.
Special Considerations for Antibiotic Formulations and
Delivery for Neonates in LMICs
Specific consideration must be given to antibiotic formulations
and delivery mechanisms for neonates and young children in the
developing country setting [46,47]. Darmstadt and colleagues
have identified several key issues including the availability of
extended interval dosing (.24 hours), safety and efficacy of
intramuscular dosing, clearance mechanisms given the inability to
closely monitor laboratory tests and fluid status, supply logistics
and storage, ease of dilution and administration, drug stability,
availability of multiple versus single use vials, availability of oral
suspension/syrup, and variable gastrointestinal absorption of oral
antibiotics in newborns and during illness [22,27]. A recent case
study for the UN Commission on Life-Saving Commodities
identified several challenges to availability and use of injectable
antibiotics in LMICs [21,48]. Providing intravenous or frequent
dosing antibiotics is difficult in low-income countries where human
resources are limited and the placement of neonatal and pediatric
IV catheters requires special skills and training. In three African
SPAs, intravenous catheters were only available in 27% of first-
level facilities. Intramuscular injection may therefore be the
preferred delivery mechanism in the community and first-level
facilities, and novel mechanisms have been tested for delivery,
including Uniject and Microneedle patch [21]. Ceftriaxone
powder must be reconstituted in sterile water and may only be
stored for 24 hours afterwards, thus 1 g vials may lead to waste in
low-volume or acuity facilities. Gentamicin requires close moni-
toring given risk of renal and ototoxicity; however, this may often
not be possible in LMIC settings. Future work should assess safety
of specific neonatal formulations and challenges/barriers to
administration, storage, and supply logistics.
While treatment with injectable antibiotics is standard of care
for treating serious neonatal infections in high-income settings,
feasibility may be limited in developing countries where availabil-
ity and administration are challenges within weak health systems,
and simplified regimens including oral antibiotics may be
preferable to none [27]. A meta-analysis showed that communi-
ty-based case management of neonatal pneumonia may result in
significant reductions in neonatal (27%, 95% CI 18%–35%) and
pneumonia-specific mortality (42%, 95% CI 22%–57%); four of
the six included trials used oral antibiotics. The recently completed
Figure 7. Meta-analysis of the logit of the prevalence of non-prescription over-the-counter antibiotic use by young infants and
children in low- and middle-income countries. Effect size is the Logit (prevalence of antibiotic purchases that were obtained over the counter
without a prescription).
doi:10.1371/journal.pmed.1001741.g007
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Simplified Antibiotic Therapy Trials in Bangladesh, Pakistan,
Democratic Republic of Congo, Kenya, and Nigeria will compare
the efficacy of simpler regimens to treat neonatal sepsis utilizing
less frequent injections and oral amoxicillin [49–51]. In the
SEARCH trial conducted in Gadichiroli, India, cotrimoxazole in
combination with gentamicin [27] was highly effective in reducing
neonatal sepsis case fatality by 60%. In a later community-based
study in Karachi, Pakistan treatment failure with cotrimoxazole-
gentamicin was significantly higher than penicillin-gentamicin
[17]. Amoxicillin and cotrimoxazole were both highly available
and low cost, and could be administered by parents. Thus,
administration of oral antibiotics, if demonstrated to have
equivalent effectiveness, may hold promise for increasing access
to treatment of pSBI in LMICs.
Non-prescription Antibiotic Use
This work confirms that informal and over-the-counter
mechanisms for obtaining antibiotics are a substantial market in
developing countries and may account for up to 25% of antibiotic
purchases for children under five in LMICs. The lack of data on
neonatal use and the diversity of conditions being treated were
limitations. The limited data indicate that use may be lower
among young infants than children. However, these data highlight
a critical area for future work and the importance of monitoring
appropriate antibiotic use in developing countries. Newborns have
special considerations regarding dosing, metabolism, and adverse
effects that require closer monitoring than older children, and
render unmonitored antibiotic use more hazardous. Furthermore,
rates of counterfeit medications are high in LMICs, with a median
prevalence of 29% [52].
Antibiotic Resistance
The emergence of antibiotic resistance as a result of inappro-
priate antibiotic use is a huge, emerging concern in LMICs, and
has been recently highlighted in the WHO Global Report on
Surveillance of Antimicrobial Resistance [53]. Our work has
identified potential areas of antibiotic overuse in LMICs, both
from parental self-medication without prescriptions, as well as the
health workers’ use of sign-based algorithms with low specificity.
Zaidi and colleagues previously reviewed data on antibiotic
resistance among hospital-acquired pathogens in LMICs and
reported alarmingly high rates of resistance—over 50% of E. coli
and Klebsiella were resistant to gentamicin and .40% to
cefotaxime [8]. Multidrug resistance is becoming more common
(75% of gram negative organisms in Africa [54]) as well as
resistance to second- and third-line antimicrobial agents (for
example with Klebsiella 51% cefotaxime resistant, and 37%
amikacin resistant) [8]. One study in a developing country
neonatal intensive care unit showed that using 3rd generation
cephalosporins as first-line treatment for sepsis was associated with
18-fold increased risk of the development of antibiotic resistance
[55]. In a recent review of community-acquired neonatal
pathogens, the most common pathogens (S. aureus, E. coli, and
Klebsiella) were .40% resistant (or had reduced sensitivity) to the
combination of penicillin and gentamicin or 3rd generation
cephalosporins [18]. In particular, Klebsiella was not susceptible
(at .50%) to any antibiotic tested (penicillin, gentamicin,
chloramphenicol, or 3rd generation cephalosporins) [18]. In the
WHO global surveillance report, high rates of resistance (.50%)
of E. coli and Klebsiella to 3rd generation cephalosporins as well as
methicillin-resistant S. aureus (MRSA) have now been widely
reported in almost all WHO regions [53]. The emergence of
antimicrobial resistance will reduce the efficacy of treatment and
narrow the armamentarium of available medications for treating
neonatal sepsis in the future generations. Zaidi and colleagues
suggest that 70% of hospital-acquired neonatal infections in low-
resource settings may not be covered by empiric typical first-line
regimens for treating neonatal sepsis (ampicillin and gentamicin)
[8], and a recent review of community-acquired bacteremia has
also questioned the efficacy and appropriateness of WHO’s
current recommended antibiotics for neonatal sepsis [18],
particularly for second-line therapy given the risk of resistance
propagation with third-generation cephalosporins. There is even
more limited data available regarding the availability of medica-
tions for resistant, nosocomial infections. For example in our
review, no data were available on carbapenem and one article
cited that colistin was not procured [56]. Routine data and
surveillance on microbial etiology and resistance patterns in
LMICs are required in order to properly target treatment
guidelines.
Hospital Acquired Infections
Although not a focus of the current review, when addressing
neonatal infections in LMICs, it is critical to consider the
specific challenges of hospital-acquired infections. Rates of
neonatal infections among hospital-born babies in LMICs may
be 3–20 times higher than rates in high-income settings [8], in
large part due to unhygienic practices during labor, delivery,
and the postnatal period. In the Indian National Neonatal-
Perinatal Database, the rate of blood-culture confirmed sepsis
was 15.6/1,000 live births in 16 national referral level nurseries
[57], while in a Nigerian report, blood stream infections affected
6.8% of low birth weight babies [58]. Pathogens associated with
hospital-acquired neonatal infections are different in low-
resource settings, where over 60% may be due to gram negative
rods (Klebsiella pneumonia, E. coli, Pseudomonas, and Acineto-
bacter), which proliferate in multi-use containers of soaps and
solutions [8], and S. aureus is also common. Prolonged therapy,
empiric use of broad spectrum antibiotics, and unhygienic
practices and environments propagate the selection and rapid
spread of these highly resistant nosocomial pathogens in LMIC
facilities [8].
Study Limitations
A major limitation of this analysis was the scarcity of neonatal-
specific data, and thus to answer some of our study questions, we
expanded the age range of our population to include young infants
and children under five. Some of the summary statistics
represented few surveys for a region, and/or we made assumptions
regarding higher concentrations or different formulations to
project to neonates. The pricing data were not adjusted for
inflation. Given the landscape nature of the review, the scope of
the review was broad and it is possible that the individual searches
or search terms may have missed articles. However, we conducted
separate detailed searches, including multiple search terms for
each of the three original research questions detailed in the web
appendix, and searched a wide range of databases, unpublished
gray literature sources and donor websites, and bibliographies of
sentinel articles. Our grey literature searches however were
limited, as we did not consult existing programs, researchers, or
governments. This outreach should be pursued in future work,
some of which is currently being addressed in the Every Newborn
Action Plan. Future efforts also need to be made to routinely
collect data on WHO Essential Medications for Children in
standardized surveys (SPAs, WHO/HAI), specifically on neonatal
formulations (lower concentrations and procaine benzylpenicillin)
as well as to assess the quality and validity of IMNCI evaluations in
young infants in SPAs.
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Conclusions
Improving diagnosis and access to treatment for neonatal
infections are critical steps to reducing neonatal morbidity and
mortality. Frontline health workers may be trained to accurately
detect pBI, but ensuring adequate quality of program implemen-
tation remains a challenge in large-scale programs. The availabil-
ity of injectable agents to treat neonatal sepsis was generally low
with few data on neonatal formulations. Furthermore, over-the-
counter mechanisms for obtaining antibiotics were common and
needs improved monitoring and regulation in order to avert the
propagation of antibiotic resistance. The development of novel,
low-cost, and user-friendly diagnostics to improve the accuracy of
detecting neonatal infections may play a critical role in improving
access to treatment and reducing inappropriate antibiotic use in
low-resource settings. Concerted efforts by governments, policy-
makers, and the pharmaceutical industry are needed to improve
the availability and pricing of life-saving antimicrobial agents in
LMICs.
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Editors’ Summary
Background. Neonatal mortality—death that occurs during
the first 28 days of life—accounts for nearly half of all the
deaths that occur in children before they reach their fifth
birthday. Worldwide, nearly 3 million neonatal deaths occur
every year. Three bacterial infections—sepsis (infection of
the bloodstream), pneumonia (infection of the lungs), and
meningitis (infection of the brain’s protective covering)—are
responsible for nearly a quarter of all neonatal deaths. Babies
born in low- and middle-income countries (LMICs) are at
particularly high risk of developing neonatal bacterial
infections because the risk factors for these infections, which
include maternal infections and unhygienic delivery care, are
more common in LMICs than in high-income countries.
Babies born in LMICs are also at a high risk of dying from
bacterial infections because access to appropriate medical
care and antibiotics is often poor.
Why Was This Study Done? To reduce neonatal deaths
from bacterial infections in LMICs, health care experts need
to identify the factors that limit access to medical care and
antibiotics in these countries. Are babies dying because
health care providers fail to diagnose neonatal bacterial
infections, because antibiotics are not available in first-line
health facilities, or for some other reason? In this systematic
review and meta-analysis, the researchers investigate
access to treatment for neonatal bacterial infections in
LMICs by first asking whether frontline health workers in
LMICs can accurately diagnose bacterial infections in
neonates and young infants (babies less than 2 months
old). Next, they ask whether antibiotics for treating
neonatal infections are available and affordable in LMICs.
Finally, they ask how often antibiotics are procured for
young children (children up to the age of 5 years) without a
prescription. A systematic review uses pre-defined criteria
to identify all the research on a given topic; meta-analysis
uses statistical methods to combine the results of several
studies.
What Did the Researchers Do and Find? The researchers
identified 37 published studies, 46 surveys of drug availabil-
ity and affordability in LMICs (Health Access International
databases), and eight surveys of the capacity of health
facilities in LMICs to provide quality health care services
(service provision assessments) that met their inclusion
criteria. Meta-analysis of six studies indicated that a
combination of simple clinical signs for the diagnosis of
bacterial infection in children predicted very severe disease
in young infants with a sensitivity of 87% and a specificity of
62% (‘‘sensitivity’’ indicates the percentage of true positives
detected by a test; ‘‘specificity’’ indicates the percentage of
healthy people that a test correctly identifies as healthy)
compared to a physician’s diagnosis with laboratory testing.
Meta-analysis of eight studies indicated that frontline health
workers (for example, community health workers) diagnosed
very severe disease (including possible bacterial infection) in
young infants with a sensitivity of 82% and a specificity of
69% compared to trained physicians. The national surveys
analyzed indicated that first-level (primary) health facilities
in Africa and South Asia had low, variable stocks of
recommended first-line injectable antibiotics and that the
cost of these drugs was high. By contrast, some oral
antibiotics were widely available at low cost in most regions.
Finally, meta-analysis of 11 studies indicated that, in LMICs,
25% of antibiotic purchases for the treatment of young
children were obtained without a prescription.
What Do These Findings Mean? These findings suggest
that trained frontline health workers should be able to
identify most young infants who have possible bacterial
infections in LMICs but may also diagnose bacterial
infections in many young infants who are not infected. This
may lead to the inappropriate use of antibiotics and facilitate
the emergence of antibiotic resistance. These findings also
show that the availability and affordability of first-line
injectable antibiotics is low in many health facilities in Africa
and Asia. The lack of neonatal-specific data on illness
recognition, antibiotic formulations and availability, and
other aspects of this systematic review and meta-analysis
are likely to limit the accuracy of these findings. Neverthe-
less, the researchers suggest that, to decrease the neonatal
death toll in LMICs, governments, policymakers, and the
pharmaceutical industry need to work together to improve
the diagnosis of neonatal bacterial infections and to increase
the availability, affordability, and appropriate use of antibi-
otics for the treatment of these infections.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001741.
N WHO provides information on global efforts to reduce
global child mortality and on ending preventable neonatal
deaths (available in several languages)
N The United Nations Children’s Fund (UNICEF) works for
children’s rights, survival, development, and protection
around the world; it provides information on global efforts
to reduce child mortality , and its Childinfo website provides
detailed statistics about neonatal survival and health; its
‘‘Committing to Child Survival: A Promise Renewed’’
webpage includes links to its 2013 progress report and to
videos about ending preventable child deaths
N The WHO has published a report entitled UN Commission
on Life Saving Commodities for Women and Children
N The Healthy Newborn Network (NHH) is an online
community of more than 80 partner organizations that
addresses critical knowledge gaps in newborn health; its
website includes information on neonatal infections in
LMICs
N Kidshealth, a resource provided by the not-for-profit
Nemours Foundation, has information for parents on
neonatal infections (in English and Spanish)
N The MedlinePlus Encyclopedia has a page on neonatal
sepsis (in English and Spanish)
N A personal story about fatal neonatal bacterial meningitis
is available on the website of Meningitis UK, a not-for-
profit organization; the site also includes a survivor story
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